Short answer
Travere Therapeutics, Inc. (TVTX) filed an 8-K current report with the SEC on April 14, 2026 reporting Item 8.01 (Other Events). FDA approval expands FILSPARI into FSGS patients aged 8 and older without nephrotic syndrome.
Travere Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- FDA approval expands FILSPARI into FSGS patients aged 8 and older without nephrotic syndrome
- Estimated U.S. addressable population exceeds 30,000 patients
- First FDA-approved medicine for FSGS, extending FILSPARI beyond IgA nephropathy
- DUPLEX showed 48% proteinuria reduction versus 27% for irbesartan at Week 108
- Commercial upside depends on launch execution, reimbursement, market adoption, and manufacturing scale-up
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Travere Therapeutics, Inc. 8-K filings
Get the next TVTX 8-K as it lands
Follow TVTX for push alerts, or ask the research agent what this filing means.